Asana Appoints CMO
This article was originally published in Scrip
Asana BioSciences, a clinical-stage biopharmaceutical company focused on targeted anticancer therapies, has appointed Louis Denis chief medical officer (CMO). Recently, Denis headed the US medical team for pipeline candidates and strategic partnerships at Boehringer Ingelheim and has also held similar strategic and leadership positions in clinical development and medical affairs at Pfizer.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.